

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 451/00, 451/04, 451/06 C07D 451/14, 453/02, 453/06 C07D 487/08, 498/08 A61K 31/395, 31/435</p>	A1	<p>(11) International Publication Number: WO 92/10494</p> <p>(43) International Publication Date: 25 June 1992 (25.06.92)</p>
<p>(21) International Application Number: PCT/GB91/02173</p> <p>(22) International Filing Date: 6 December 1991 (06.12.91)</p> <p>(30) Priority data: 9027098.4 13 December 1990 (13.12.90) GB</p> <p>(71) Applicant (for all designated States except US): BEECHAM GROUP P.L.C. [GB/GB]; Four New Horizons Court, Harlequi Avenue, Brentford, Middlesex TW8 9EP (GB).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only) : KING, Francis, David [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).</p>		<p>(74) Agents: JONES, Pauline et al.; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.</p> <p>Published With international search report.</p>

(54) Title: PHARMACEUTICALS



(I)

(57) Abstract

Compounds of formula (I) and pharmaceutically acceptable salts thereof wherein the variable groups are as defined in the specification.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

-1-

PHARMACEUTICALS

This invention relates to novel compounds having pharmacological activity, to a process for their preparation and their use as pharmaceuticals.


UK Patent No. 1571447 (Societe D'Etudes Scientifiques et Industrielles de L'Ile-de-France) describes a group of benzamide derivatives having dopamine antagonist activity.

10

A group of novel compounds have now been discovered, which compounds are 5-HT₃ receptor antagonists.

Accordingly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof:

20



(I)

wherein

25 R₁ is hydrogen, halo, nitro, amino, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R₂ is halo, C₁₋₆ alkyl or C₁₋₆ alkoxy;

A is (poly)methylene of 1-3 carbon atoms, optionally substituted by one or two C₁₋₆ alkyl group(s);

30 L is O or NH; and

Z is a di-azacyclic or azabicyclic side chain; having 5-HT₃ receptor antagonist activity.

-2-

Suitable examples of alkyl moieties in R_1 and R_2 and A include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl.

5 Suitable examples of halo moieties include fluoro, chloro and bromo, preferably chloro or bromo.

Often R_1 is hydrogen and R_2 is chloro or bromo.

10 A is preferably unsubstituted polymethylene of 1 or 2 carbon atoms (i.e. O-A-O is methylenedioxy or ethylenedioxy).

Suitable examples of Z are described in the art relating to 5-HT₃ receptor antagonists, ie. as follows:

15

- i) GB 2125398A (Sandoz Limited)
- ii) GB 2152049A (Sandoz Limited)
- iii) EP-A-215545 (Beecham Group p.l.c.)
- iv) EP-A-214772 (Beecham Group p.l.c.)
- 20 v) EP-A-377967 (Beecham Group p.l.c.)
- vi) PCT/GB91/01629 (Beecham Group p.l.c.)
- vii) EP-A-358903 (Dianippon)

Particular side chains of interest are depicted thus:

25


Tropane

30




Granatane

35




Oxa/thia/aza-granatane

5

Quinuclidine


10

15 Isoquinuclidine

20

Isogranatane

25

Oxa/thia-isogranatane

30



35

Isotropane

5



or



wherein

R is hydrogen or methyl; and X is oxygen, sulphur or
10 nitrogen optionally substituted by C₁₋₆ alkyl, C₃₋₈
cycloalkyl, C₃₋₈ cycloalkyl C₁₋₄ alkyl, phenyl, naphthyl,
phenyl C₁₋₄ alkyl or naphthyl C₁₋₄ alkyl wherein a phenyl or
naphthyl moiety is optionally substituted by one or more of
halo, C₁₋₆ alkoxy or C₁₋₆ alkyl.

15

Side chains Z of particular interest include tropane,
oxagranatane and azagranatane, where R is methyl. Suitable
values for N-substituents when X is N are as described in
PCT/GB91/01629, for example, iso-propyl or ethyl.

20

L is preferably NH.

Alternatively, COL in formula (I) may be replaced by a
bioisostere therefor, for example, 1,2,4-oxadiazole and the
25 other groups of structure h) described in EP-A-377967
(Beecham Group p.l.c.).

The pharmaceutically acceptable salts of the compounds of
the formula (I) include acid addition salts with
30 conventional acids such as hydrochloric, hydrobromic, boric,
phosphoric, sulphuric acids and pharmaceutically acceptable
organic acids such as acetic, tartaric, maleic, citric,
succinic, benzoic, ascorbic, methanesulphonic, α -keto
glutaric, α -glycerophosphoric, and glucose-1-phosphoric
35 acids.

-5-

The pharmaceutically acceptable salts of the compounds of the formula (I) are usually acid addition salts with acids such as hydrochloric, hydrobromic, phosphoric, sulphuric, citric, tartaric, lactic and acetic acid.

5

Preferably the acid addition salt is the hydrochloride salt.

Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds R_X-T wherein R_X is C_{1-6} alkyl, phenyl- C_{1-6} alkyl or C_{5-7} cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of R_X include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl. Suitable examples of T include halide such as chloride, bromide and iodide.

Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.

20 The compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred to.


It will of course be realised that some of the compounds of the formula (I) have chiral or prochiral centres and thus are capable of existing in a number of stereoisomeric forms including enantiomers. The invention extends to each of these stereoisomeric forms (including enantiomers), and to mixtures thereof (including racemates). The different stereoisomeric forms may be separated one from the other by the usual methods.

35

The invention also provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, which process comprises reacting a compound of formula (II):

5

10



(II)

with a compound of formula (III):

15

HLZ'

(III)

or a reactive derivative thereof, when L is O;

wherein R_1' , R_2' and/or Z' are R_1 , R_2 and/or Z respectively or groups or atoms convertible thereto; Q_1 is a leaving group; and the remaining variables are as hereinbefore defined; and thereafter optionally converting R_1' , R_2' and/or Z' to another group or atom R_1 , R_2 , R_3 or Z ; and optionally forming a pharmaceutically acceptable salt of the resultant compound of formula (I).

Examples of leaving groups Q_1 , displaceable by a nucleophile, include halogen such as chloro and bromo, C_{1-4} alkoxy, such as CH_3O and $\text{C}_2\text{H}_5\text{O}-$, $\text{PhO}-$, activated hydrocarbyloxy, such as $\text{Cl}_5\text{C}_6\text{O}-$ or $\text{Cl}_3\text{CO}-$, or a nitrogen-linked heterocycle, such as imidazole.

If a group Q_1 is a halide, then the reaction is preferably carried out at non-extreme temperatures in an inert non-hydroxylic solvent, such as benzene, dichloromethane, toluene, diethyl ether, tetrahydrofuran (THF) or

-7-

dimethylformamide (DMF). It is also preferably carried out in the presence of an acid acceptor, such as an organic base, in particular a tertiary amine, such as triethylamine, trimethylamine, pyridine or picoline, some of which can also function as the solvent. Alternatively, the acid acceptor can be inorganic, such as calcium carbonate, sodium carbonate or potassium carbonate. Temperatures of 0°-100°C, in particular 10-80°C are suitable.

- 10 If a group Q_1 is C_{1-4} alkoxy, phenoxy or activated hydrocarbyloxy then the reaction is preferably carried out in an inert polar solvent, such as toluene or dimethylformamide. It is also preferred that the group Q_1 is Cl_3CO- and that the reaction is carried out in toluene at
15 reflux temperature.

When L is O the compound of formula (III) may be in the form of a reactive derivative thereof, which is often a salt, such as the lithium, sodium or potassium salt.

20

- It will be apparent that compounds of the formula (I) containing an R_1 or R_2 group which is convertible to another such group are useful novel intermediates. i.e. a hydrogen substituent is convertible to a halogen substituent by
25 halogenation using conventional halogenating agents.

Z' when other than Z may be wherein R is replaced by R' which is a hydrogenolysable protecting group which is benzyl optionally substituted by one or two groups selected from
30 halo, C_{1-4} alkoxy and C_{1-4} alkyl. Such benzyl groups may, for example, be removed, when R_1/R_2 is not halogen, by conventional transition metal catalysed hydrogenolysis to give compounds of the formula (I) wherein R is hydrogen.

- 35 This invention also provides a further process for the preparation of a compound of the formula (I) wherein R is

methyl or a pharmaceutically acceptable salt thereof, which comprises N-methylating a compound of formula (I) wherein R is hydrogen, and optionally forming a pharmaceutically acceptable salt of the resulting compound of the formula (I). In this further process of the invention 'N-methylation' may be achieved by reaction with a compound CH_3Q_3 wherein Q_3 is a leaving group.

Suitable values for Q_3 include groups displaced by nucleophiles such as Cl, Br, I, OSO_2CH_3 or $\text{OSO}_2\text{C}_6\text{H}_4\text{PCH}_3$, preferably Cl, Br or I.

The reaction may be carried out under conventional alkylation conditions for example in an inert solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate. Generally the reaction is carried out at non-extreme temperature such as at ambient or slightly above.

Alternatively, 'N-methylation' may be effected under conventional reductive alkylation conditions.

Interconverting R in the compound of the formula (III) before coupling with the compound of the formula (II) is also possible. Such interconversions are effected conveniently under the above conditions. It is desirable to protect any amine function with a group readily removable by acidolysis such as a C_{2-7} alkanoyl group, before R/Z interconversion.

30

It is often convenient in the preparation of such a compound of formula (III) to prepare the corresponding compound wherein the methyl group is replaced by alkoxycarbonyl.

Such compounds may then be reduced using a strong reductant such as lithium aluminium hydride to the corresponding

35

compound of formula (II).

The compounds of formula (II) are known or are preparable analogously to, or routinely from, known compounds, such as
5 described in UK 1571278.

Compounds of the formula (III) are generally prepared from the corresponding exocyclic keto derivative of the azabicyclic side chain, prepared by condensation methods,
10 often using a substituted piperidine.

They may be prepared by processes described in the aforementioned Patent Publications relating to values of the side chain Z.

15

It will be realised that in the compounds of the formula (I) having a tropane, granatane or oxa/thia/aza-granatane side chain, the -COL- linkage has an **endo** orientation with respect to the ring of the bicyclic moiety to which it is
20 attached. A mixture of **endo** and **exo** isomers of the compound of the formula (I) may be synthesised non-stereospecifically and the desired isomer separated conventionally therefrom e.g. by chromatography; or alternatively the **endo** isomer may if desired be synthesised from the corresponding **endo** form
25 of the compound of the formula (II). Corresponding geometric isomeric pairs are possible for the isoquinuclidine, isogranatane, oxa/thia-isogranatane and isotropane side chains.

30 Pharmaceutically acceptable salts of the compounds of this invention may be formed conventionally.

The salts may be formed for example by reaction of the base compound of formula (I) with a pharmaceutically acceptable
35 organic or inorganic acid.

-10-

The compounds of the present invention are 5-HT₃ receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of pain, emesis, CNS disorders and gastrointestinal disorders. Pain includes migraine, cluster headache, trigeminal neuralgia and visceral pain; emesis, includes, in particular, that of preventing vomiting and nausea associated with cancer therapy, post-operative emesis, and nausea associated with migraine. Examples of such cancer therapy include that using cytotoxic agents, such as platinum complexes including cisplatin, and also doxorubicin and cyclophosphamide, particularly cisplatin; and also radiation treatment. CNS disorders include anxiety, psychosis, cognitive disorders such as senile dementia and age associated memory impairment (AAMI), and drug dependence. Gastrointestinal disorders include irritable bowel syndrome and diarrhoea.

5-HT₃ receptor antagonists may also be of potential use in the treatment of obesity, arrhythmia, and/or disorders associated with myocardial instability.

The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Such compositions are prepared by admixture and are usually adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are preferred, since they are more convenient for general use.

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional

-11-

excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with an enteric coating.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate.

Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

30

Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such

35

-12-

as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.

5 The oral compositions may be prepared by conventional methods of blending, filling or tableting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course,
10 conventional in the art.

For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle
15 and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic,
20 preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

25 Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is
30 included in the composition to facilitate uniform distribution of the compound of the invention.

The invention further provides a method of treatment or prophylaxis of pain, emesis, CNS disorders and/or
35 gastrointestinal disorders in mammals, such as humans, which comprises the administration of an effective amount of a

-13-

compound of the formula (I) or a pharmaceutically acceptable salt thereof.

An amount effective to treat the disorders herein- before
5 described depends on the relative efficacies of the
compounds of the invention, the nature and severity of the
disorder being treated and the weight of the mammal.

However, a unit dose for a 70kg adult will normally contain
0.05 to 1000mg for example 0.5 to 500mg, of the compound of
10 the invention. Unit doses may be administered once or more
than once a day, for example, 2, 3 or 4 times a day, more
usually 1 to 3 times a day, that is in the range of
approximately 0.0001 to 50mg/kg/day, more usually 0.0002 to
25 mg/kg/day.

15


No adverse toxicological effects are indicated within the
aforementioned dosage ranges.

The invention also provides a compound of formula (I) or a
20 pharmaceutically acceptable salt thereof for use as an
active therapeutic substance, in particular for use in the
treatment of pain, emesis, CNS disorders and/or
gastrointestinal disorders.

25 The following Examples illustrate the preparation of
compounds of formula (I).

Example 1

endo-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-7-chloro-1,4-benzodioxan-5-carboxamide (E1)



A solution of 7-chloro-1,4-benzodioxan-5-carboxylic acid (UK patent 1,571,278, Societe D'Etudes Scientifiques et Industrielles de L'Ile-de-France) (0.25g) in SOCl_2 (5 mL) was stirred at room temperature for 2h. The reaction mixture was evaporated to dryness and re-evaporated with xylene (2 x 20 mL). The residue was dissolved in CH_2Cl_2 (20 mL) and treated with a solution of endo-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine (0.2g) in CH_2Cl_2 (10 mL). After standing at room temperature overnight, the reaction mixture was washed with sat. NaHCO_3 (50 mL), dried (K_2CO_3) and evaporated to dryness. The residue was purified by column chromatography (Al_2O_3 , eluting with CH_2Cl_2) to give the title compound, converted to its HCl salt with ethanolic HCl, precipitation with Et_2O . (0.31 g).

^1H NMR (d^6 -DMSO) δ 8.40, 8.20 (2-d, 1H)

7.10 (s, 2H)

4.65-4.15 (m, 5H including 4.30, brs, 4H)

3.65-3.45 (m, 2H)

2.81, 2.79 (2-s, 3H)

2.55-2.30 (m, 4H)

2.20-1.95 (m, 2H)

1.82-1.53 (m, 2H)


1.55-1.35 (m, 2H)

-15-

Prepared similarly was:

Example 2

5 endo-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-
1,3-benzodioxole-4-carboxamide (E2)



¹H NMR (CDCl₃) δ 7.51 (d, 1H)
6.88 (d, 1H)
6.72 (brd, 1H)
6.13 (s, 2H)
4.58-4.38 (m, 1H)
3.09 (brd, 2H)
2.60-2.40 (m, 5H including 2.50 s, 3H)
1.98 (brd 3H)
1.59-1.42 (m, 1H)
1.31 (dt, 2H)
1.03 (brd, 2H)

5-HT₃ Receptor Antagonist Activity

Compounds are evaluated for antagonism of the von Bezold-Jarisch reflex evoked by 5-HT in the anaesthetised rat according to the following method:


Male rats 250-350g, are anaesthetised with urethane (1.25g/kg intraperitoneally) and blood pressure and heart rate are recorded as described by Fozard J.R. et al., J. Cardiovasc. Pharmacol. 2, 229-245 (1980). A submaximal dose of 5-HT (usually 6µg/kg) is given repeatedly by the intravenous route and changes in heart rate quantified. Compounds are given intravenously and the concentration required to reduce the 5-HT-evoked response to 50% of the control response (ED₅₀) is then determined.

The compounds of the Examples are both active at a dose of 10µg/kg i.v.

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:

5



10

wherein

R_1 is hydrogen, halo, nitro, amino, C_{1-6} alkyl or C_{1-6} alkoxy;

15

R_2 is halo, C_{1-6} alkyl or C_{1-6} alkoxy;

A is (poly)methylene of 1-3 carbon atoms, optionally substituted by one or two C_{1-6} alkyl group(s);

L is O or NH; and

20 Z is a di-azacyclic or azabicyclic side chain; having 5-HT₃ receptor antagonist activity.

2. A compound according to claim 1 wherein R_1 is hydrogen and R_2 is chloro or bromo.

25

3. A compound according to claim 1 or 2 wherein O-A-O is methylenedioxy or ethylenedioxy.


4. A compound according to any one of claims 1 to 3 wherein the side chain Z is tropane, granatane, oxa/thia/aza-granatane, quinuclidine, isoquinuclidine, isogranatane, oxa/thia-isogranatane or isotropane.

30

-18-

5. A compound according to claim 4 wherein Z is tropane, oxagranatane or azagranatane.
6. A compound according to any one of claims 1 to 5 wherein L is NH.
7. **endo-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-7-chloro-1,4-benzodioxan-5-carboxamide.**
- 10 8. **endo-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-1,3-benzodioxole-4-carboxamide.**
9. A pharmaceutically acceptable salt of a compound according to claim 7 or 8.
- 15 10. A compound according to claim 1 substantially as defined herein with reference to the Examples.
11. A process for the preparation of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, which process comprises reacting a compound of formula (II):

25



(II)

30 with a compound of formula (III):

HLZ'

(III)

-19-

or a reactive derivative thereof, when L is O;

wherein R_1' , R_2' and/or Z' are R_1 , R_2 and/or Z respectively or groups or atoms convertible thereto; Q_1 is a leaving group; and the remaining variables are as hereinbefore defined; and thereafter optionally converting R_1' , R_2' and/or Z' to another group or atom R_1 , R_2 , R_3 or Z ; and optionally forming a pharmaceutically acceptable salt of the resultant compound of formula (I).

10

12. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

15 13. A method of treatment or prophylaxis of pain, emesis, CNS disorders and/or gastrointestinal disorders in mammals, such as humans, which comprises the administration of an effective amount of a compound according to claim 1.

20 14. A compound according to any one of claims 1 to 11 for use as an active therapeutic substance.

15. A compound according to any one of claims 1 to 11 for use in the treatment of pain, emesis, CNS disorders and/or
25 gastrointestinal disorders.

16. The use of a compound according to any one of claims 1 to 11 in the manufacture of a medicament for the treatment and/or prophylaxis of pain, emesis, CNS disorders and/or
30 gastrointestinal disorders.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 91/02173

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int. Cl. 5 C 07 D 451/00 C 07 D 451/04 C 07 D 451/06
 C 07 D 451/14 C 07 D 453/02 C 07 D 453/06 C 07 D 487/08
 C 07 D 498/08 A 61 K 31/395 A 61 K 31/435

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols		
Int. Cl. 5	C 07 D 451/00 C 07 D 498/00	C 07 D 453/00 A 61 K 31/00	C 07 D 487/00

Documentation Searched other than Minimum Documentation
 to the Extent that such Documents are Included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP, A, 0083737 (BEECHAM GROUP PLC) 20 July 1983, see abstract; claims 1, 11-13; page 22, lines 12-22 ---	1-4, 6, 11, 12, 14-16
X	CH, A, 651561 (DELALANDE S.A.) 30 September 1985, see abstract; claims 1, 13 ---	1-3, 6
X	GB, A, 1571447 (SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE) 16 July 1980, see claims 1, 15, 17, 92-95 ---	1-6, 12, 14-16
X	EP, A, 0377967 (BEECHAM GROUP PLC) 18 July 1990, see claims 1, 2, 11, 14, 15, 17 --- -/-	1, 4-6, 11, 12, 14-16

¹⁰ Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed


"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search 17-02-1992	Date of Mailing of this International Search Report 24. 03. 92
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer  Danielle van der Haas

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	
X	EP,A,0041817 (BEECHAM GROUP LIMITED) 16 December 1981, see abstract; claims 1,8,13 ---	1-6,11, 12,14- 16
X	EP,A,0226267 (BEECHAM GROUP PLC) 24 June 1987, see abstract; claims 1,5,6,9,13-15 -----	1-4,6, 11,12, 14-16

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 13 because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1 (iv)

Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers _____, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANHANG
zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

ANNEX
to the International Search
Report to the International Patent
Application No.

ANNEXE
au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/GB91/02173 SAE 54087

In diesem Anhang sind die Mitglieder
der Patentfamilien der im obenge-
nannten internationalen Recherchenbericht
angeführten Patentdokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visée ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP-A1- 83737	20-07-83	AU-A1-91538/82 ES-A1- 518204 ES-A5- 518204 ES-A1- 8402299 JP-A2-58110586 AU-A1-84932/82 DE-C0- 3268378 EP-A1- 67615 EP-B1- 67615 JP-A2-58032878 US-A - 4499099 ZA-A - 8209256 EP-A1- 69482 ES-A1- 513160 ES-A5- 513160 ES-A1- 8307805 ES-A1- 520622 ES-A5- 520622 ES-A1- 8403899 JP-A2-58010580 US-A - 4459300 AU-A1-85390/82 EP-A1- 68700 ES-A1- 513561 ES-A5- 513561 ES-A1- 8307244 JP-A2-58010579 ZA-A - 8204579 EP-A1- 69481 JP-A2-58010578 ZA-A - 8204238	23-06-83 01-02-84 29-02-84 16-04-84 01-07-83 23-12-82 20-02-86 22-12-82 08-01-86 25-02-83 12-02-85 28-09-83 12-01-83 01-08-83 31-08-83 01-11-83 01-04-84 02-05-84 01-07-84 21-01-83 10-07-84 06-01-83 05-01-83 01-07-83 29-07-83 16-10-83 21-01-83 27-04-83 12-01-83 21-01-83 27-04-83
CH-A5- 651561		BE-A4- 890962 CA-A1- 1209574 CH-A - 651561 DE-A1- 3144183 DE-C2- 3144183 ES-A2- 507394 ES-A6- 507394 ES-A2- 8301979 FR-A2- 2493848 FR-B2- 2493848 GB-A1- 2088364 GB-B2- 2088364 IT-A0- 8124835 IT-A - 1140040 JP-A2-57108090 JP-B4-63044753 LU-A1- 83737 NL-A - 8105042 SE-A - 8106425 SE-B - 448457 SE-C - 448457 US-A - 4434170 ZA-A - 8107675 BE-A1- 890979 LU-A - 82083 BE-A1- 890979 CA-A1- 1175023 CA-A2- 1175024	03-05-82 12-08-86 30-09-85 12-08-82 23-01-92 01-02-83 11-02-83 01-04-83 14-05-82 16-05-86 09-06-82 31-10-84 03-11-81 24-09-86 05-07-82 06-09-88 01-09-83 01-06-82 08-05-82 23-02-87 02-07-87 28-02-84 27-10-82 04-05-82 10-09-81 04-05-82 25-09-84 25-09-84

DE-C0-	3177004	20-04-89
DK-A -	2933782	30-06-82
EP-A1-	64058	10-11-82
EP-B1-	64058	15-03-89
ES-A1-	506943	01-02-83
ES-A5-	506943	26-02-83
ES-A1-	8302474	16-04-83
ES-A1-	516574	16-12-83
ES-A5-	516574	14-01-84
ES-A1-	8401326	01-03-84
IT-A0-	8124855	04-11-81
IT-A -	1140261	24-09-86
JP-T2-	57501823	14-10-82
JP-B4-	2025626	05-06-90
US-A -	4316576	23-02-82
WO-A1-	8201480	13-05-82
AU-A1-	54610780	24-07-80
AU-B2-	542537	28-02-85
BE-A1-	881134	14-07-80
CA-A1-	1130286	24-08-82
CA-A2-	1160227	10-01-84
CH-A -	646969	28-12-84
CH-A -	647520	31-01-85
DE-A1-	3001328	24-07-80
DE-C2-	3001328	08-06-89
ES-A1-	487721	16-06-80
ES-A5-	487721	25-06-80
FR-A2-	2476088	21-08-81
FR-B2-	2476088	04-11-83
GB-A1-	2042522	24-09-80
GB-A1-	2055374	04-03-81
GB-B2-	2055374	07-04-83
GB-B2-	2042522	13-04-83
IT-A0-	8019071	08-01-80
IT-A0-	8024713	17-09-80
IT-A -	1148801	03-12-86
JP-A2-	55108871	21-08-80
JP-A2-	56164187	17-12-81
JP-A2-	59076084	28-04-84
JP-B4-	60059915	27-12-85
MX-U -	6529	28-06-85
NL-A -	8000277	18-07-80
NL-A -	8005774	30-01-81
SE-A -	8000068	17-07-80
SE-B -	431984	12-03-84
SE-C -	431984	21-06-84
SE-B -	444941	20-05-86
SE-C -	444941	28-08-86
US-A -	4321378	23-03-82
US-A -	4329466	11-05-82
US-A -	4424358	03-01-84
US-A -	4471120	11-09-84
US-A -	4536580	20-08-85
FR-A1-	2446823	14-08-80
FR-B1-	2446823	21-10-83
ZA-A -	8000160	28-01-81
CA-A2-	1175024	25-09-84
CA-A2-	1179658	18-12-84
DK-A -	2933782	30-06-82
DE-C0-	3177004	20-04-89
EP-A1-	64058	10-11-82
EP-B1-	64058	15-03-89
JP-T2-	57501823	14-10-82
JP-B4-	2025626	05-06-90
AU-A1-	61314780	13-11-80
AU-B2-	539517	04-10-84

GB-A - 1571447

16-07-80

AR-A1-	219709	15-09-80
AT-A -	5696777	15-01-80
AT-B -	358034	11-08-80
AU-A1-	2750777	08-02-79
AU-B2-	516033	14-05-81
BE-A1-	857350	01-02-78
BG-A3-	36496	15-11-84
CA-A1-	1114371	15-12-81
CH-A -	629198	15-04-82
CS-B2-	216246	29-10-82
DD- C-	133237	20-12-78
DE-A1-	2734270	16-02-78
DE-C2-	2760414	17-05-90
DE-C2-	2734270	21-06-90
DK-A -	3469777	05-02-78
DK-B -	152366	22-02-88
DK-C -	152366	25-07-88
EG-A -	12716	30-09-79
ES-A1-	461175	01-12-78
ES-A5-	461175	02-01-79

FI-A	-	772362	05-02-78
FI-B	-	63938	31-05-83
FI-C	-	63938	12-09-83
FR-A1-	2360305		03-03-78
FR-B1-	2360305		18-04-80
GB-A	-	1571278	09-07-80
GR-A	-	61351	26-10-78
HK-A	-	403782	24-09-82
HK-A	-	404782	24-09-82
HU-B	-	179064	28-08-82
IE-B	-	45646	20-10-82
IE-B	-	45647	20-10-82
IL-A0-	52644		31-10-77
IL-A0-	66138		30-09-82
IL-A1-	52644		31-01-84
IL-A1-	66138		31-01-84
IN-A	-	145473	21-10-78
JP-A2-	53018570		20-02-78
JP-A2-	53028181		16-03-78
JP-B4-	57037594		10-08-82
JP-A2-	57167914		16-10-82
JP-B4-	61017832		09-05-86
JP-B4-	62059090		09-12-87
LU-A	-	77897	09-02-78
MC-A	-	1154	17-04-78
MW-A	-	20777	13-12-78
NL-A	-	7708616	07-02-78
NL-B	-	172063	01-02-83
NL-C	-	172063	01-07-83
NO-A	-	772739	07-02-78
NO-B	-	152133	29-04-85
NO-C	-	152133	07-08-85
NZ-A	-	184816	14-11-80
PH-A	-	17710	19-11-84
PH-A	-	18629	23-08-85
PH-A	-	22114	01-06-88
PL-D	-	200066	11-09-78
PL-B1-	111071		30-08-80
PT-A	-	66865	01-07-77
PT-B	-	66865	29-12-78
RO-P	-	72963	24-11-81
SE-A	-	7708849	05-02-78
SE-A	-	8206546	17-11-82
SE-A0-	8206546		17-11-82
SE-B	-	437027	04-02-85
SE-B	-	440776	19-08-85
SE-C	-	440776	28-11-85
SE-B	-	453390	01-02-88
SE-C	-	453390	19-05-88
SU-D	-	716523	15-02-80
US-A	-	4186135	29-01-80
US-A	-	4248885	03-02-81
US-A	-	4255580	10-03-81
US-A	-	4268512	19-05-81
US-A	-	4306072	15-12-81
US-A	-	4323503	06-04-82
YU-A	-	1882777	21-01-83
ZA-A	-	7704701	31-01-79
ZM-A	-	60777	21-05-79
IE-B	-	45647	20-10-82
PH-A	-	17988	28-02-85
YU-B	-	40005	30-06-85
BR-A	-	8101903	06-10-81
JP-A2-	56138452		29-10-81
PH-A	-	17988	28-02-85
US-A	-	4333886	08-06-82
BR-A	-	8101903	06-10-81
JP-A2-	56138451		29-10-81
JP-B4-	62032350		14-07-87
PH-A	-	17547	19-09-84
US-A	-	4347195	31-08-82

EP-A2-	377967	18-07-90	AU-A1-	46081/89	21-06-90
			CA-AA-	2005131	13-06-90
			DK-A0-	6252/89	11-12-89
			DK-A	- 6252/89	14-06-90
			EP-A3-	377967	25-09-91
			GB-A0-	8829079	25-01-89
			JP-A2-	2202890	10-08-90
			ZA-A	- 8909434	24-04-91

EP-A1-	41817	16-12-81	JP-A2-	57031689	20-02-82
			US-A	- 4352802	05-10-82

AU-B2-	594351	08-03-90
DK-A0-	3408786	17-07-86
DK-A -	3408786	20-01-87
ES-AF-	2000524	01-03-88
GB-A0-	8518236	29-08-85
JP-A2-6	2030785	09-02-87
NZ-A -	216880	27-09-89
PT-A -	83016	01-08-86
US-A -	4826839	02-05-89
US-A -	4883874	28-11-89
ZA-A -	8605328	24-06-87
ES-YA-	1000319	16-07-88
